Back to News
Market Impact: 0.2
Pilatus Biosciences Strengthens Global Intellectual Property Position for Lead CD36-Targeted Immunometabolic Therapy
Source: Business Wire
Healthcare & BiotechPatents & Intellectual Property
Pilatus Biosciences announced that it has strengthened the global intellectual-property position for PLT012, its lead CD36-targeted immunotherapy. The announcement supports protection of the company’s lead oncology-development asset, although no clinical data, financial terms, or commercialization timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal